Once‐Daily, Controlled‐Release Tramadol and Sustained‐Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial

Beaulieu, André; Peloso, Paul M.; Haraoui, Boulos; Bensen, W.; Thomson, G. T. D.; Wade, John; Quigley, Patricia; Eisenhoffer, John; Harsanyi, Zoltan; Darke, Andrew C.

doi:10.1155/2008/903784

Cited by 58 publications

(54 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 31 Direct comparisons between non-opioids and opioids are rare and contradictory: a randomised controlled trial in patients with osteoarthritis showed controlled release tramadol to be as effective and as well tolerated as sustained release diclofenac, 32 whereas two other randomised controlled studies showed celecoxib to be more effective than tramadol with fewer adverse events in patients with chronic low back pain. 33 In both studies, the duration of treatment was only six weeks.…”

Section: How Do Opioids Compare With Other Drugs For Chronic Non-malimentioning

confidence: 99%

Opioids for chronic non-cancer pain

Freynhagen

Geißlinger

Schug

2013

BMJ

View full text Add to dashboard Cite

Section: How Do Opioids Compare With Other Drugs For Chronic Non-malimentioning

confidence: 99%

Opioids for chronic non-cancer pain

Freynhagen

Geißlinger

Schug

2013

BMJ

View full text Add to dashboard Cite

“…Однако, по данным серии РКИ [82][83][84], его анальгетический потенциал (при использовании в дозе 200-400 мг/сут) не выше, чем у НПВП, а переносимость су-щественно хуже. Примерно у 15-20% больных, получаю-щих трамадол, лечение приходится прерывать из-за побоч-ных эффектов -сонливости, тошноты, головокружения, нарушения сна, запора и т. д. Главным достоинством трама-дола является низкий риск развития серьезных осложнений со стороны ЖКТ и ССС.…”

Section: о с н о в н ы е ф а к т о р ы р и с к а н п в п -а с с о ц иunclassified

Analgesic treatment, by using a systemic algorithm

Евгеньевич¹,

Алексеева²

2015

RJTAO

View full text Add to dashboard Cite

Хроническая мышечно-скелетная боль (МСБ) -ос-новное проявление болезней костно-мышечной систе-мы (БКМС), в наибольшей степени определяющее стра-дания пациентов, потерю трудоспособности и социаль-ной активности, а также существенные затраты на лече-ние и диагностические мероприятия. Более того, высту-пая в роли фактора, способствующего прогрессирова-нию заболеваний сердечно-сосудистой системы (ССС), хроническая МСБ не только ухудшает качество жизни пациентов с БКМС, но и уменьшает ее продолжитель-ность [1][2][3][4][5].В то же время отчетливое «старение» современной по-пуляции приводит к непрерывному росту числа больных с патологией опорно-двигательного аппарата, прежде всего остеоартрозом (ОА) и хронической неспецифической бо-лью в нижней части спины (НБНЧС). Соответственно, рас-тет и число лиц, страдающих МСБ. Поэтому в последние годы хроническая МСБ рассматривается как глобальная ме-

show abstract

“…Most of these only reported complications with an incidence of greater than 5 or 10% or serious adverse advents that were considered related to the study medication. The majority of trials did not report any infectious complications (Roth et al 2000;Caldwell et al 2002;Raja et al 2002;Watson et al 2003;Babul et al 2004;Hale et al 2005;Matsumoto et al 2005;Gana et al 2006;Kivitz et al 2006;Hale et al 2007;Beaulieu et al 2008;Gordon et al 2010). Only 6 out of 18 trials reported infectious complications but their incidence was too low to detect statistically significant differences (see Table 3; (Gimbel et al 2003;Markenson et al 2005;Langford et al 2006;Burch et al 2007;Katz et al 2007;O'Donnell et al 2009).…”

Section: Relationship Between Opioid Use and Infectious Complicationsmentioning

confidence: 99%

Immunosuppressive Effects of Opioids—Clinical Relevance

Brack

Rittner

Stein

2011

J Neuroimmune Pharmacol

View full text Add to dashboard Cite

Opioid-induced immunosuppression has been demonstrated in cell culture experiments and in animal models. This is in striking contrast to the paucity of confirmatory studies in humans. This review describes the basic pharmacokinetics and -dynamics of opioid use in patients. It summarizes the major findings on opioid use and infectious complications in intensive care unit (ICU) patients, in patients with acute or chronic non-malignant pain, and in intravenous drug users (IDU). The limitations of studies in each area are discussed. For example, ethical concerns may complicate randomized placebo-controlled trials (RCT) in acute postoperative pain and for a large part of ICU patients. Importantly, most studies in patients with chronic (non-malignant) pain only inadequately report infectious complications in relation to opioid use since their incidence is usually not considered to be drug related. Infectious complications in IDUs are very frequent but cannot easily be distinguished from risk behavior or risk environment. In summary, convincing clinical evidence is lacking that opioids per se increase the rate of infectious complications in most patient categories. From a clinical standpoint, important unresolved issues are i) selection of relevant animal models, ii) opioid selection and discontinuation, and iii) the role of coexisting diseases and concomitant other medications.

show abstract

Once‐Daily, Controlled‐Release Tramadol and Sustained‐Release Diclofenac Relieve Chronic Pain due to Osteoarthritis: A Randomized Controlled Trial

Abstract: CR tramadol is as effective as SR diclofenac in the treatment of pain due to knee or hip osteoarthritis, with the potential for fewer of the serious side effects that characterize nonsteroidal anti-inflammatory drug administration.

Cited by 58 publications

References 32 publications

Opioids for chronic non-cancer pain

Opioids for chronic non-cancer pain

Analgesic treatment, by using a systemic algorithm

Immunosuppressive Effects of Opioids—Clinical Relevance

Contact Info

Product

Resources

About